大博医疗2025年三季报显示，前三季度公司主营收入18.76亿元，同比上升22.69%；归母净利润4.25亿 元，同比上升77.03%；扣非净利润3.46亿元，同比上升63.99%；其中2025年第三季度，公司单季度主营 收入6.66亿元，同比上升17.82%；单季度归母净利润1.8亿元，同比上升77.49%；单季度扣非净利润1.23 亿元，同比上升38.44%；负债率24.53%，投资收益580.87万元，财务费用-2387.47万元，毛利率 71.23%。大博医疗（002901）主营业务：医用高值耗材的生产、研发与销售。 证券之星消息，截至2025年12月18日收盘，大博医疗(002901)报收于48.87元，上涨0.74%，换手率 0.62%，成交量1.8万手，成交额8806.6万元。 12月18日的资金流向数据方面，主力资金净流入336.83万元，占总成交额3.82%，游资资金净流出 542.49万元，占总成交额6.16%，散户资金净流入205.65万元，占总成交额2.34%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近90天内共有1家机构给出评级，买入评级1家。 资金流向名 ...

该股主要指标及行业内排名如下： 大博医疗2025年三季报显示，前三季度公司主营收入18.76亿元，同比上升22.69%；归母净利润4.25亿 元，同比上升77.03%；扣非净利润3.46亿元，同比上升63.99%；其中2025年第三季度，公司单季度主营 收入6.66亿元，同比上升17.82%；单季度归母净利润1.8亿元，同比上升77.49%；单季度扣非净利润1.23 亿元，同比上升38.44%；负债率24.53%，投资收益580.87万元，财务费用-2387.47万元，毛利率 71.23%。大博医疗（002901）主营业务：医用高值耗材的生产、研发与销售。 该股最近90天内共有1家机构给出评级，买入评级1家。 证券之星消息，截至2025年12月16日收盘，大博医疗(002901)报收于49.05元，上涨0.22%，换手率 0.91%，成交量2.64万手，成交额1.28亿元。 12月16日的资金流向数据方面，主力资金净流入1839.02万元，占总成交额14.36%，游资资金净流入 129.1万元，占总成交额1.01%，散户资金净流出1968.12万元，占总成交额15.37%。 近5日资金流向一览见下表： 资金流 ...

Core Viewpoint - The stock of Dabo Medical (002901) has shown a decline in price and mixed capital flow, with significant net outflows from retail investors, while institutional investors have shown some interest [1][3]. Group 1: Stock Performance - As of December 2, 2025, Dabo Medical's stock closed at 48.96 yuan, down 1.01%, with a turnover rate of 0.81% and a trading volume of 23,400 hands, resulting in a transaction amount of 116 million yuan [1]. - The net inflow of main funds on December 2 was 8.74 million yuan, accounting for 7.54% of the total transaction amount, while retail investors had a net outflow of 8.20 million yuan, representing 7.08% of the total [1]. Group 2: Financial Metrics - Dabo Medical's total market value is 20.27 billion yuan, with a net asset of 3.44 billion yuan and a net profit of 425 million yuan, ranking 12th, 43rd, and 17th respectively in the medical device industry [2]. - The company reported a year-on-year revenue increase of 22.69% for the first three quarters of 2025, with a total revenue of 1.876 billion yuan and a net profit increase of 77.03% to 425 million yuan [2]. - The gross profit margin stands at 71.23%, significantly higher than the industry average of 51.22%, indicating strong profitability [2]. Group 3: Institutional Ratings - In the last 90 days, one institution has issued a buy rating for Dabo Medical, indicating some level of confidence in the stock's potential [3].

| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-01 | 49.46 | 2.68% | 615.41万 | 4.28% | 477.33万 | 3.32% | -1092.73万 | -7.60% | | 2025-11-28 | 48.17 0.19% | | -232.34万 | -5.74% | 88.25万 | 2.18% | 144.09万 | 3.56% | | 2025-11-27 | 48.08 0.69% | | -140.71万 | -2.53% | -419.95万 | -7.54% | 560.66万 | 10.06% | | 2025-11-26 | 47.75 0.00% | | -84.04万 | -1.55% | -201.79万 | -3.73% | 285.83万 | 5.28% | | 2025-11-25 | 47.75 0.95% | | -213.52万 | - ...

Core Viewpoint - The stock of Dabo Medical (002901) has shown a slight increase of 1.38% on October 31, 2025, closing at 50.04 yuan, with notable fluctuations in capital flow and strong financial performance in recent quarters [1][3]. Financial Performance - For the first three quarters of 2025, Dabo Medical reported a main revenue of 1.876 billion yuan, a year-on-year increase of 22.69% [3]. - The net profit attributable to shareholders reached 425 million yuan, up 77.03% year-on-year [3]. - The third quarter alone saw a main revenue of 666 million yuan, reflecting a 17.82% increase year-on-year, and a net profit of 180 million yuan, which is a 77.49% increase year-on-year [3]. Market Position - Dabo Medical's total market capitalization stands at 20.718 billion yuan, significantly higher than the industry average of 11.561 billion yuan, ranking 12th in the industry [3]. - The company has a gross margin of 71.23%, which is above the industry average of 51.22%, ranking 16th in the industry [3]. - The return on equity (ROE) is reported at 12.83%, substantially higher than the industry average of 0.15%, ranking 7th in the industry [3]. Capital Flow Analysis - On October 31, 2025, the net outflow of main funds was 146,400 yuan, accounting for 0.06% of the total transaction amount, while retail investors experienced a net outflow of 1.239 million yuan, representing 5.43% of the total transaction amount [1][2]. - Over the past five days, the stock has seen varying capital flows, with significant retail and speculative fund movements impacting the overall trading dynamics [2].

Group 1 - Chuanfa Longmang's wholly-owned subsidiary plans to invest 660 million yuan to establish a joint venture for a 175,000 tons/year high-pressure lithium iron phosphate project in Sichuan Mianzhu, with a total investment of 1.961 billion yuan [1] - The joint venture will be co-owned by Jiangxi Shenghua New Materials (51%) and Deyang Chuanfa Longmang (49%) [1] - Chuanfa Longmang specializes in the production and sales of various phosphate products, including lithium iron phosphate [1] Group 2 - Sino Medical's COMETIU self-expanding intracranial drug-coated stent system registration application was not approved by the National Medical Products Administration [2] - Sino Medical focuses on the research, development, production, and sales of high-end interventional medical devices [3] Group 3 - Jincheng Pharmaceutical's subsidiaries have been selected for the 11th batch of national drug centralized procurement [3] - Jincheng Pharmaceutical is engaged in the research, development, production, and sales of pharmaceutical intermediates and formulations [3] Group 4 - Zhongke Lanyun reported a 4.29% increase in revenue to 1.302 billion yuan and a 2.17% increase in net profit to 211 million yuan for the first three quarters [4] - The company specializes in wireless audio SoC chip research, design, and sales [5] Group 5 - Dabo Medical achieved a 22.69% increase in revenue to 1.876 billion yuan and a 77.03% increase in net profit to 425 million yuan for the first three quarters [6] - Dabo Medical focuses on the production, research, and sales of high-value medical consumables [7] Group 6 - Dayang Electric reported a 3.81% increase in revenue to 9.180 billion yuan and a 25.95% increase in net profit to 845 million yuan for the first three quarters [8][9] - The company operates in the electric motor sector, focusing on building and home appliance motors and automotive components [9] Group 7 - Fudan Microelectronics reported a 12.70% increase in revenue to 3.024 billion yuan but a 22.69% decrease in net profit to 330 million yuan for the first three quarters [10][11] - The company specializes in the design, development, and testing of large-scale integrated circuits [11] Group 8 - Shaanxi Energy reported a 2.83% decrease in revenue to 16.359 billion yuan and a 3.23% decrease in net profit to 2.417 billion yuan for the first three quarters [12][13] - The company is involved in thermal power generation and coal production and sales [13] Group 9 - Runhe Software reported a 12.86% increase in revenue to 2.719 billion yuan but a 29.01% decrease in net profit to 78.57 million yuan for the first three quarters [14][15] - The company focuses on financial technology, smart IoT, and smart energy [15] Group 10 - Shenzhen Gas reported an 8.63% increase in revenue to 22.528 billion yuan but a 13.08% decrease in net profit to 918 million yuan for the first three quarters [16][17] - The company specializes in urban gas supply and comprehensive energy services [17] Group 11 - Light Media reported a 150.81% increase in revenue to 3.616 billion yuan and a 406.78% increase in net profit to 2.336 billion yuan for the first three quarters [18][19] - The company is engaged in the investment, production, and distribution of film projects [19] Group 12 - Dazhong Mining's subsidiary obtained a mining license for the Hunan Jijiao Mountain lithium mine, with a resource amount of 490 million tons, equivalent to approximately 3.2443 million tons of lithium carbonate [19] - The company specializes in iron ore mining and production [19] Group 13 - Yirui Technology reported a 14.22% increase in revenue to 1.549 billion yuan and a 20.61% increase in net profit to 471 million yuan for the first three quarters [20] - The company focuses on the research, production, and sales of digital X-ray detectors and related solutions [20] Group 14 - TCL Zhonghuan reported a 4.48% decrease in revenue to 121.572 billion yuan and a net loss of 5.777 billion yuan for the first three quarters [21][22] - The company specializes in the research, production, and sales of photovoltaic silicon wafers, cells, and modules [22] Group 15 - Huangshan Tourism reported an 8.75% increase in revenue to 1.535 billion yuan but an 11.02% decrease in net profit to 253 million yuan for the first three quarters [23][24] - The company provides tourism and leisure services [24] Group 16 - Mountain Outside Mountain reported a 39.79% increase in revenue to 584 million yuan and a 68.68% increase in net profit to 105 million yuan for the first three quarters [25][26] - The company specializes in the research, production, and sales of blood purification equipment and services [26] Group 17 - Huajin Capital reported a 16.36% increase in revenue to 349 million yuan and a 185.62% increase in net profit to 104 million yuan for the first three quarters [27] - The company focuses on investment management and electronic device manufacturing [27] Group 18 - Datang Power reported a 1.82% decrease in revenue to 89.345 billion yuan but a 51.48% increase in net profit to 6.712 billion yuan for the first three quarters [28][29] - The company primarily engages in thermal power generation [29] Group 19 - Datang Power announced the acquisition of a 50% stake in Anhui Electric Power for 1 yuan, which will result in full ownership of Anhui Electric Power [30] - The company focuses on thermal power generation [30] Group 20 - Kairun Co. reported a 22.94% increase in revenue to 3.719 billion yuan but a 13.38% decrease in net profit to 278 million yuan for the first three quarters [31] - The company specializes in the research, design, production, and sales of leisure bags and related products [31] Group 21 - Dafu Technology reported a 1.95% increase in revenue to 1.764 billion yuan but a net loss of 170 million yuan for the first three quarters [32] - The company focuses on the research, production, and sales of RF products and automotive components [32] Group 22 - Dafu Technology plans to publicly transfer 49% of its stake in Dasheng Graphite [34] - The company specializes in the research, production, and sales of RF products and automotive components [34]

Core Insights - The stock of Dabo Medical (002901) closed at 53.43 yuan on October 27, 2025, with a 1.15% increase and a trading volume of 17,100 hands, resulting in a transaction amount of 91.35 million yuan [1] Financial Performance - Dabo Medical reported a main revenue of 1.21 billion yuan for the first half of 2025, a year-on-year increase of 25.55% - The net profit attributable to shareholders was 244 million yuan, up 76.69% year-on-year - The net profit excluding non-recurring items was 223 million yuan, reflecting an 82.64% year-on-year increase - In Q2 2025, the company achieved a single-quarter main revenue of 660 million yuan, a 22.96% year-on-year increase, and a net profit of 141 million yuan, up 84.47% year-on-year [3] Market Position - Dabo Medical's total market capitalization is 22.121 billion yuan, significantly higher than the industry average of 11.652 billion yuan, ranking 11th out of 124 in the medical device industry - The company's net assets stand at 3.233 billion yuan, below the industry average of 3.871 billion yuan, ranking 44th out of 124 - The company has a gross margin of 71.01%, which is above the industry average of 51.35%, ranking 17th out of 124 [3] Investment Sentiment - Over the last 90 days, one institution has given a buy rating for Dabo Medical [4]

Core Viewpoint - The stock of Dabo Medical (002901) shows a slight increase in price and mixed capital flow, indicating potential investor interest despite some outflows from retail investors [1][2]. Group 1: Stock Performance - As of October 22, 2025, Dabo Medical's stock closed at 52.25 yuan, up by 0.17% with a turnover rate of 0.48% and a trading volume of 13,800 hands, resulting in a transaction amount of 72.41 million yuan [1]. - The capital flow data on October 22 indicates a net inflow of 1.44 million yuan from institutional investors, accounting for 1.99% of the total transaction amount, while retail investors experienced a net outflow of 0.78 million yuan, representing 1.08% of the total [1][2]. Group 2: Recent Capital Flow Overview - Over the past five days, the stock has experienced fluctuating capital flows, with significant net outflows from retail investors on several days, including a net outflow of 26.84 million yuan on October 17 [2]. - The highest net inflow from institutional investors occurred on October 16, amounting to 6.44 million yuan, while the largest net outflow was recorded on October 17 [2]. Group 3: Company Financials and Industry Comparison - Dabo Medical's total market capitalization is 21.63 billion yuan, significantly higher than the industry average of 11.61 billion yuan, ranking 11th out of 124 in the medical device sector [3]. - The company reported a net profit of 244 million yuan for the first half of 2025, reflecting a year-on-year increase of 76.69%, with a gross margin of 71.01%, which is above the industry average of 51.42% [3]. - Dabo Medical's return on equity (ROE) stands at 7.6%, outperforming the industry average of 1.91%, indicating strong profitability relative to its peers [3].

Core Viewpoint - The stock of Dabo Medical (002901) has shown a decline in price and mixed capital flow, indicating potential volatility in investor sentiment and market performance [1][2]. Group 1: Stock Performance - As of October 16, 2025, Dabo Medical's stock closed at 54.78 yuan, down 1.33% with a turnover rate of 0.78% and a trading volume of 22,400 hands, resulting in a transaction amount of 124 million yuan [1]. - Over the past five days, the stock has experienced fluctuations, with a notable drop of 2.94% on October 15, 2025, and a previous increase of 0.77% on October 13, 2025 [2]. Group 2: Capital Flow Analysis - On October 16, 2025, the net inflow of main funds was 6.44 million yuan, accounting for 5.2% of the total transaction amount, while retail investors saw a net outflow of 11.24 million yuan, representing 9.07% of the total [1][2]. - The capital flow data indicates that institutional investors have shown interest, with one buy rating given in the last 90 days [4]. Group 3: Financial Metrics and Industry Comparison - Dabo Medical's total market value is 22.68 billion yuan, significantly higher than the industry average of 11.875 billion yuan, ranking 10th in the industry [3]. - The company reported a net profit of 244 million yuan for the first half of 2025, a year-on-year increase of 76.69%, with a gross margin of 71.01%, which is above the industry average of 51.85% [3]. - The company's return on equity (ROE) stands at 7.6%, outperforming the industry average of 1.8%, indicating strong profitability relative to its equity base [3].

Core Viewpoint - The stock of Dabo Medical (002901) has experienced a decline of 3.05% as of October 14, 2025, closing at 57.2 yuan, with significant net outflows from retail and speculative investors [1][2]. Financial Performance - Dabo Medical reported a main revenue of 1.21 billion yuan for the first half of 2025, representing a year-on-year increase of 25.55% [3] - The net profit attributable to shareholders was 244 million yuan, up 76.69% year-on-year [3] - The second quarter of 2025 saw a single-quarter main revenue of 660 million yuan, a 22.96% increase year-on-year [3] - The company achieved a gross margin of 71.01% and a net margin of 21.42% [3] Market Position - Dabo Medical's total market capitalization is 23.682 billion yuan, ranking 9th in the medical device industry [3] - The company has a price-to-earnings ratio of 48.48, which is lower than the industry average of 66.45 [3] - The return on equity (ROE) stands at 7.6%, significantly higher than the industry average of 1.8% [3] Capital Flow Analysis - On October 14, 2025, the net inflow of main funds was 8.5985 million yuan, accounting for 3.81% of the total transaction amount [1][2] - Over the past five days, the stock has seen fluctuations in capital flow, with notable net outflows from retail investors [2]